| Carfilzomib | multiple myeloma, in all type of patients | vs bortezomib | by 21% | by 47% | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| death (overall survival) | 0.79 [0.65 0.96] | p=0.04 | 0 | 929 | 1 | ENDEAVOR, | | progression or death (progression free survival PFS) | 0.53 [0.44 0.64] | p=0.04 | 0 | 929 | 1 | ENDEAVOR, |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients | Trial | Studied treatment | Control | Patients |
|---|
| ENDEAVOR, 2016 | carfilzomib with dexamethasone | bortezomib with dexamethasone | patients with relapsed or refractory multiplemyeloma who had one to three previous treatments |
|
| Carfilzomib | multiple myeloma, in all type of patients | vs bortezomid | - | - | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| death (overall survival) | no data | | progression or death (progression free survival PFS) | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients | Trial | Studied treatment | Control | Patients |
|---|
| ECOG-ACRIN, | | | | | CLARION, | | | |
|
| Carfilzomib | multiple myeloma, in all type of patients | vs lenalidomide and dexamethasone alone | by 21% | by 31% | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| death (overall survival) | 0.79 [0.63 0.99] | p=0.04 | 0 | -18 | 1 | ASPIRE, | | progression or death (progression free survival PFS) | 0.69 [0.57 0.83] | p=0.04 | 0 | -18 | 1 | ASPIRE, |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients | Trial | Studied treatment | Control | Patients |
|---|
| ASPIRE, 2014 | carfilzomib with lenalidomide and dexamethasone | lenalidomide and dexamethasone alone | patients with relapsed multiple myeloma |
|
| Carfilzomib | multiple myeloma, in all type of patients | vs low-dose corticosteroids | NS | - | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| death (overall survival) | 0.98 [0.76 1.25] | p=1.00 | 0 | 315 | 1 | FOCUS, | | progression or death (progression free survival PFS) | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients | Trial | Studied treatment | Control | Patients |
|---|
| FOCUS, 2017 | carfilzomib monotherapy | low-dose corticosteroids and optional cyclophosphamide | relapsed and refractory multiple myeloma (RRMM) |
|
